28 - 29 August, 2012, Novotel Clarke Quay Hotel, Singapore
Download the Brochure
Click here for Download Centre
"This event is a good start and will achieve another future milestone for years to come!"
- Director, Ministry of Health, Malaysia
"Good discussion on challenges in clinical trials."
- Regulatory Specialist, HSA, Singapore
"First-hand information on sharing among the experts in the field."
- Senior Manager, National University Health System, Singapore
"Good mix of topics on clinical trials."
- Senior CRM, Allergan
"Valuable practical scientific issues to be used back in the office!"
- Senior Clinical Scientist, Protech Pharmaservices Corporation
"Great opportunity to meet industry experts in Asia!"
- Clinical Research Manager, Daiichi Sankyo Taiwan
"IQPC brings together the experts you can learn from!"
- Director Patient Safety, Vanthys Pharmaceutical Development
Become a Pharma IQ Member and receive our weekly newsletter!
Connect to a global Pharma IQ social network
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
(inclusive of morning break)
Regulatory approval in China for early phase clinical trials is always one the most critical challenges. In this workshop, Zaiqi will examine the regulatory requirements, approval process and effective regulatory strategies for early phase clinical trials registration in China. Most importantly, it will focus on how lessons learnt can be applied by sponsors.
This workshop will address:
Vice President, Clinical Services
Frontage Lab China
Dr. Chun(Charlie)Xu has over 28 years of medical practice, academic research, and industry experience in China, Canada, and the U.S. Dr. Xu has a wealth of experience in major aspects of clinical development including medical affairs, operation, and regulatory filing/compliance in US and Canada. He has now moved back to China in 2008 taking the leadership role in clinical operations in one of the major CROs in China before joining Frontage, and now serves as VP Clinical Services in Frontage Lab China.
[ Register Now ]